4-[2-[5-[4-(4,5-dimethyl-1H-imidazol-2-yl)phenyl]imidazo[4,5-b]pyrazin-3-yl]ethyl]morpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[2-[5-[4-(4,5-dimethyl-1H-imidazol-2-yl)phenyl]imidazo[4,5-b]pyrazin-3-yl]ethyl]morpholine
• 化学式: C₂₂H₂₅N₇O
• 分子量: 403.5
• InChiKey: ZVWHRBOLLSLUNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  84.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Treatment of cancer with TOR kinase inhibitors
  申请人：Signal Pharmaceuticals, LLC

  公开号：US11166950B2

  公开（公告）日：2021-11-09

  Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

  本文提供了治疗或预防患者实体瘤、非霍奇金淋巴瘤或多发性骨髓瘤的方法，包括向患有实体瘤、非霍奇金淋巴瘤或多发性骨髓瘤的患者施用有效量的TOR激酶抑制剂。
• INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY
  申请人：SIGNAL PHARMACEUTICALS, LLC

  公开号：US20140113905A1

  公开（公告）日：2014-04-24

  Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3β or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3β or p70S6K1.
• TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
  申请人：SIGNAL PHARMACEUTICALS, LLC

  公开号：US20160008356A1

  公开（公告）日：2016-01-14

  Provided herein are methods for treating or preventing a neuroendocrine tumor of non-gut origin in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a neuroendocrine tumor of non-gut origin.
• US9155736B2
  申请人：——

  公开号：US9155736B2

  公开（公告）日：2015-10-13
• US9557338B2
  申请人：——

  公开号：US9557338B2

  公开（公告）日：2017-01-31